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ABSTRACT: Many respiratory drugs are not available in formulations suitable for
infants and toddlers. Efficacy and safety research is mostly restricted to older children.
However, respiratory drugs are frequently used in children for common diseases like
asthma, upper and lower respiratory tract infections, rhinitis and sinusitis. The
unlicensed and off-label use of respiratory drugs in children were studied.
A population-based cohort study was conducted by using the computerised medical
records in the Integrated Primary Care Information project. The study population
comprised a random sample from all children aged 0–16 yrs who were registered with a
general practitioner in 1998. All prescriptions for respiratory drugs during the study
period were classified according to their licensing and off-label status.
The study population comprised 13,426 patients (51.7% male, median age 8.7 yrs), of
whom 2,502 (19%) received 5,253 prescriptions for respiratory drugs in 1998. A total of
3,306 (62.9%) prescriptions concerned licensed drugs. Of the remaining 1,947
prescriptions (37.1%), 882 (16.8%) were unlicensed for use in children, and 1,065
(20.3%) were prescribed off-label. The 1-yr cumulative risk of receiving an unlicensed
or off-label prescription was 45% among children with at least one prescription for a
respiratory drug.
This population-based study showed that a large proportion of respiratory drugs
prescribed by the general practitioner are unlicensed for use in children, or licensed but
prescribed in an off-label manner. Results have to be interpreted with caution because
they may unjustly suggest inaccurate prescribing, whereas it may be difficult to treat
children with respiratory symptoms and diseases, because for many respiratory drugs
paediatric data on safety and efficacy are insufficient. These findings underline the
importance of research on suitable formulations, dosages and efficacy of respiratory
drugs in children.
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The extent and nature of unlicensed and off-label drug
prescription in paediatric clinical care has been the subject of
several surveys in Europe [1–7] and these consistently showed
that a very large proportion of prescribed drugs are either
unlicensed for use in children or used outside the terms of the
product license ("off-label"). Several studies also provide
information on the extent of this type of drug prescription in
children with respiratory diseases, but information provided
is often limited.
Respiratory drugs are used for several of the most common
paediatric diseases such as asthma, upper and lower res-
piratory tract infections, rhinitis and sinusitis; conditions that
are treated in general practice rather than in clinical care
[8–12]. Previous research by the present group revealed that
70% of available respiratory drugs in the Netherlands are not
fully licensed for use in children, and many of these (80%) are
registered only for specific age/weight groups [13]. Many of
the children with respiratory problems present themselves
long before they have reached the age range given in the
product information of many respiratory drugs. As part of
a larger project [14], a large cohort study was conducted
in general practice to assess the extent and nature of
unlicensed and off-label prescription of respiratory drugs in
children.
Methods
Setting
All data were retrieved from the Integrated Primary Care
Information (IPCI) project, a longitudinal observational data-
base with data from computer-based patient records from a
group of 150 general practitioners (GPs) in the Netherlands.
As of 2001, the IPCI database contains data on a cumulative
number of 485,000 patients. The system complies with
European Union guidelines on the use of medical data for
medical research and has been proven valid for pharmaco-
epidemiological research [15].
Design
A population-based cohort study was conducted in a
dynamic population of children in the IPCI database who
were permanently registered with one of the participating
general practices between 1 January 1998 and 31 December
1998 [14]. In 1998, 53,702 children were registered in the IPCI
database. Since this research required manual review of all
prescriptions 25% were randomly sampled from the population,
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which formed the primary study population (n=13,426). All
study subjects were followed from 1 January 1998, or the date
of registration in the GP practice, whichever was latest, until
the earliest of one of the following censoring points: death,
reaching the age of 17 yrs, transferring out of the practice, or
end of the study period.
Classification of prescriptions
From the prescription file, all prescriptions plus their
dosage regimens and indications issued to the primary study
population in 1998 were extracted. Respiratory drugs were
categorised into "nasal preparations" (ATC R01), "oropharyn-
geal preparations" (ATC R02), "antiasthmatics" (ATC R03),
"cough and cold medications" (ATC R05) and "antihista-
mines for systemic use" (ATC R06).
All prescriptions for respiratory drugs were classified regard-
ing their licensing status [3]. The main mutually exclusive
categories were: 1) licensed for children; 2) licensed, but used
off-label; and 3) unlicensed for children. Further classification
of prescriptions was performed as described earlier [14]. As a
reference source for classification, the official product license
was used, as approved by the Dutch Medicines Evaluation
Board and the European Medicines Evaluation Agency
(EMEA).
Age was classified in line with the paediatric age definitions
provided by the EMEA [16], but the category 2–v12 yrs was
split because of heterogeneity within this age group [17]. Age
groups used were: 0–v1 month, 1 month–v2 yrs, 2–v6 yrs,
6–v12 yrs, and o12 years. Since the number of prescriptions
in the youngest age group was negligible (n=1), this group was
excluded from further analysis.
Analysis
Descriptive analyses were conducted for patient demo-
graphics, prescription data and outcome. Statistical compar-
isons consisted of independent unpaired t-tests for continuous
variables, and Chi-squared tests for discrete variables.
Confidence intervals (CI) of 95% around prevalence estimates
were based on the normal distribution.
Results
During the study period, 5,253 prescriptions concerning
respiratory drugs were issued to 2,502 patients (table 1).
The median number of respiratory drug prescriptions among
respiratory drug-using children was 1 (interquartile range
(IQR) 1–2). The median number of prescriptions was 2 per
patient per year (IQR 1–3) for antiasthmatics. Patients who
received respiratory drugs were significantly younger than the
rest of the study population (pv0.001).
The most frequently prescribed respiratory drugs were
antiasthmatics (40.7% of all prescriptions), followed by sys-
temic antihistamines (27.7%) and nasal preparations (23.2%).
Largest subclasses of drugs (in numbers of prescriptions)
were corticosteroids (18.0%), selective b2-sympathomimetics
(17.1%), systemic antihistamines (14.8%), sympathomimetics
for nasal use (12.7%) and phenothiazine derivates (8.9%), as
shown in table 2. The most frequently prescribed drugs were
salbutamol (12.7%), xylomethazoline (12.7%), promethazine
(7.4%), beclomethasone (6.5%) and fluticasone (6.5%).
Of the 5,252 prescriptions, 3,305 (62.9%) were licensed for
use in children, and prescribed in concordance with the
product license. Of the remaining 1,947 prescriptions (37.1%),
Table 1. – Characteristics of study population
Variable Respiratory drug
prescription-receiving
children
Drug
prescription-receiving
children}
Subjects 2502 6313
Male 1318 (52.7) 3066 (48.6)
Female 1184 (47.3) 3247 (51.4)
Age groups#
0–v1 month 1 (v0.1) 40 (0.6)
1 month–v2 yrs 821 (32.6) 1263 (20.0)
2–v6 yrs 947 (37.8) 1797 (28.5)
6–v12 yrs 833 (33.3) 1921 (30.4)
o12 yrs 552 (22.0) 1562 (24.7)
Data are presented as n (%) unless otherwise stated. Percentage is
calculated based on column total. #: totals do not add up to the total of
the study group, since some patients contributed to several age groups;
}: all drug prescriptions over 1998, including respiratory drugs.
Table 2. – Respiratory drug utilisation
Drug class Drug category Prescriptions Users
Total %# UL %} OL %} Total %# UL/OLz %}
Inhaled corticosteroids Antiasthmatics 943 18.0 307 32.6 488 3.6 180 36.9
Inhaled b2-sympathomimetics Antiasthmatics 898 17.1 162 18.0 300 33.4 561 4.2 318 56.7
Indifferent antihistamines§ Antihistamines for systemic use 776 14.8 299 38.5 49 6.3 517 3.9 267 51.6
Nasal sympathomimetics Nasal preparations 668 12.7 32 4.8 9 1.3 602 4.5 37 6.1
Pheothiazine derivates Antihistamines for systemic use 467 8.9 73 15.6 20 4.3 389 2.9 78 20.1
Nasal corticosteroids Nasal preparations 276 5.3 141 51.1 4 1.4 182 1.4 94 51.6
Nonsteroid antiallergic drugs Nasal preparations 200 3.8 119 59.5 4 2.0 120 0.9 75 62.5
Piperazine derivates Antihistamines for systemic use 175 3.3 15 8.6 7 4.0 119 0.9 15 12.6
Opium alkaloids and derivates Cough and cold medications 164 3.1 1 0.6 26 15.9 141 1.1 25 17.7
Parasympathomimetics Antiasthmatics 112 2.1 7 6.3 100 89.3 88 0.7 84 95.5
Expectorants Cough and cold medications 98 1.9 34 34.7 20 20.4 93 0.7 74 79.6
Mucolyticsƒ Cough and cold medications 81 1.5 28 34.6 71 0.5 26 36.6
Other drugs for nasal use## Nasal preparations 75 1.4 57 0.4
Other cough-suppressant drugs}} Cough and cold medications 75 1.4 52 69.3 61 0.5 44 72.1
Sympathomimeticszother
antiasthmaticszz
Antiasthmatics 69 1.3 68 98.6 50 0.4 50 100.0
UL: unlicensed; OL: off-label. #: percentage of total number of respiratory prescriptions (n=5252) and patients in the cohort (n=13426);
}: row
percentage; z: patients with an UL or OL prescription; §: e.g. deptropine, ketotifen, and tefenadine; ƒ: acetylcysteine and brome hexin; ##: e.g.
mupirocin and NaCl; }}: e.g. pentoxyverine;zz: e.g. fenoterolzipratropium in Berodual1.
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882 (16.8%, 95% CI 15.8–17.8) were prescriptions for unlicensed
drugs, and 1,065 (20.3%, 95% CI 19.2–21.4) were off-label
prescriptions for licensed drugs. Unlicensed drugs consisted
of modification of preparations (8.7%), drugs that lacked
information on use in children (6.6%), and drugs that were
contraindicated for use (1.4%). Prescriptions were off-label
for age (7.3%), dose (7.8%), frequency (3.8%), indication
(4.5%) or dosage form (1.1%). Drugs could be off-label for
several reasons. Unlicensed and off-label drug use differed for
the various respiratory drug classes (table 2). Off-label use
was especially high for antiasthmatic drugs (39%), and cough
and cold medication (30%). Antiasthmatic drugs were fre-
quently off-label for dose and/or indication or age/weight (14,
10 and 15%, respectively), and cough and cold medication
was mostly off-label for dose (19%). Unlicensed use was
especially high for nose preparations and antihistamines for
systemic use (24.0 and 26.4%, respectively), but off-label use
was very low in these groups; the primary reason for
unlicensed drug use for both drug classes was modification
of preparations by the pharmacy. The most frequently
prescribed unlicensed and off-label drugs were salbutamol
(inhaled, off-label for age and dose), deptropine (syrup,
unlicensed), fluticasone (inhaled, off-label for dose), terbuta-
line (inhaled, off-label for dose), and sodium cromoglycate
(nasal spray, no information on use in children).
The numbers of unlicensed and off-label prescriptions were
highest in the age group 1 month–v2 yrs (table 3). The 1-yr
cumulative risk of an unlicensed or off-label prescription was
45% (95% CI 43–47) among children with at least one
prescription for a respiratory drug. Males had a 15% (95% CI
6–25) higher chance of receiving unlicensed or off-label
prescriptions for antiasthmatics than females. For other
groups no significant differences were found.
For some infrequently used drugs (parasympathomimetics
and expectorants), the percentage of exposed children with at
least one off-label or unlicensed prescription was highest (95
and 79%, respectively). However, the percentage of children
with at least one off-label or unlicensed prescription was also
high among the drugs with the highest exposure (table 2).
Discussion
This study showed a high 1-yr cumulative risk of unlicensed
and off-label use of respiratory drugs among children who use
these drugs. In terms of prescription, 17% were unlicensed and
20% off-label. The risk of at least one off-label or unlicensed
prescription was highest among users of parasympathometics,
expectorants, sympathomimetics for inhalation and systemic
antihistamines, and was highest for young children.
These high numbers of unlicensed and off-label drug use,
however, have to be interpreted with caution because they
may unjustly suggest inaccurate prescribing. In fact, there is a
lack of properly licensed drugs for all age groups in dosage
forms that are suitable, and with dosing windows that
correspond to the needs regarding symptom relief and cure
of patients. Another reason for a cautious interpretation is the
fact that there may be a difference between the product
information and prescribing guidelines, such as given by the
Dutch College of General practitioners and in formularies
like the Physician9s Desk Reference [18], and the British
National Formulary or the Medicines for Children formulary
[19]. Therefore, not all deviations from the product informa-
tion can be qualified as errors. However, the licensing
information text of many respiratory drugs provides physi-
cians with dosage recommendations that are more restricted
than the information text in common drug formularies, which
also contain data that are based on experience, and not so
much on evidence.
The high percentage of modified preparations for children
(8.7%) is a direct result of the lack of licensed paediatric
formulations [20, 21], which requires modification of com-
mercial preparations in the pharmacies. The drug prescrip-
tions that were off-label for age were not checked for other
off-label categories like indication and dosage, since these
were not provided in the labelling information text. The
dosage form therefore seems to be correct for most pre-
scriptions, but especially in the younger children, the availa-
bility of suitable formulations is limited. Although there have
been major advances in relation to different types of inhalers
for children of different ages with asthma, such as the
turbohaler, nebuhaler and volumatic inhaler [22], knowledge
of reproducibility of dose and lung disposition is limited
[23]. Pressurised metered dose inhalers/spacers and face masks
are needed for these children [24], and parents have to be
adequately instructed to be able to apply the drug. Dose
variability for these drugs in small infants is large, and
increased by complicating factors like bad cooperation by the
wheezy infant [25].
Earlier research on unlicensed and off-label respiratory
drug use in general practice in children is scarce, except for a
study in the UK [26] that reported individual percentages
of unlicensed and off-label use for some respiratory drugs.
However, this study group was small, since only one GP
participated. Besides, the classification system used by
MCINTYRE et al. [26] for unlicensed and off-label status of
drugs differs from the system that was used for this study.
A recent study in the Netherlands based on pharmacy
dispensing records showed that 15.1% of prescriptions in that
study were off-label, and another 6.4% unlicensed. Prescrip-
tions by specialists (outpatient), prescriptions for new drugs,
prescriptions for drugs with a low use in the paediatric
population, and prescriptions for infants were risk factors for
using a systemic drug unlicensed or off-label in that study
[27]. Since the indications are not available in pharmacy
dispensing data, the indication for prescription of a drug was
not evaluated. The prescriptions in this study were also not
evaluated for dose, frequency, dosage form and route of
administration. Therefore, the results show a much lower
unlicensed and off-label use of drugs in children. However,
the authors acknowledge the risk factors as indicated by this
article. Unfortunately, they were unable to differentiate
between outpatient specialist prescriptions, continued by the
GP, and initial GP prescription.
Several measures have been taken by the Food and Drug
Administration (FDA) for the improvement of the current
"orphan status" of children regarding drug research. As part
Table 3. – Number of drug prescriptions within licensing
status
Variable Unlicensed/
off-label
Licensed
Age groups
1 month–v2 yrs 644 (65.2) 343 (34.8)
2–v6 yrs 583 (35.2) 1074 (64.8)
6–v12 yrs 422 (27.9) 1089 (72.1)
o12 yrs 298 (27.2) 799 (72.8)
Drug classes
Antiasthmatics 1008 (47.1) 1131 (52.9)
Antihistamines for systemic use 466 (32.0) 991 (68.0)
Nasal preparations 309 (25.3) 910 (74.7)
Cough and cold medication 162 (38.1) 263 (61.9)
Oropharyngeal preparations 2 (15.4) 11 (84.6)
Total 1947 (37.1) 3305 (62.9)
Data are presented as n (%). The percentages are within age group/drug
class.
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of the FDA modernisation act, the "Pediatric Exclusivity
Provision" was introduced to increase the numbers of
paediatric registrations of drugs for children. Six extra
months of patent exclusivity (the right to produce and sell a
drug) could be obtained when drugs were issued for paediatric
licensing. However, instead of intensified research on drugs
most useful for the paediatric population, such as sympathi-
comimetics, and corticosteroids for respiratory use, many of
the Written Requests that were issued for this 6-month
exclusivity were cardiovascular drugs and other drugs that are
rarely prescribed in the paediatric population but for which
an extra 6 months of exclusivity is very lucrative in adults [28].
Although this study has been conducted in the Netherlands,
where the healthcare system differs from many other European
countries, results are relevant to Europe as well. Other studies
have shown high frequency of unlicensed and off-label drug
use for other European countries [29–32], and the labelling of
drugs is equal or highly similar due to the increasing role of
the European registration authority during the last decade.
Most importantly, the conclusion that has to be drawn
regarding the licensing of respiratory drugs in children
concerns the Netherlands as well as all other countries.
Results show the high use of unlicensed and off-label use of
respiratory drugs in children, while these are among the most
commonly used drugs in children. The current shortage of
formulations and dosage forms appropriate for infants and
toddlers, especially, has to be resolved, and research on new
and older drugs should include safety and efficacy studies in
all appropriate paediatric age groups. Postmarketing surveil-
lance of paediatric drug use should be intensified in order to
increase the knowledge of safety and efficacy in a patient
group, for which drug testing is restricted by ethical and
practical boundaries.
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